Dry Eye News and Research

RSS

Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.

SAFLUTAN launched in United Kingdom and Spain

Merck Sharp & Dohme (MSD) has launched SAFLUTAN (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today.

3 Sep 2009

Advanced Instruments' next-generation website facilitates easy retrieval of product and application information

Advanced Instruments has introduced a next-generation Web site that dramatically enhances the customer's online business experience when purchasing osmometers, cryoscopes, and microbiological laboratory instruments.

24 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Medicare information for caregivers now available on NIHSeniorHealth

If you're caring for an older friend or family member, you've probably had questions about Medicare, the federal health insurance program for adults 65 and older and people under age 65 with disabilities.

13 May 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Folic acid, B vitamins in Animi-3 may prevent vision loss

A new study by researchers at Harvard Medical School has found that combining essential B vitamins, including B6, B12, and folic acid, lower risk of developing age-related macular degeneration (AMD), one of the leading causes of vision loss among older Americans.

4 Mar 2009

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

25 Feb 2009

Immunosuppressant medication cyclosporine may be cost-effective for dry eye syndrome

A topical eye emulsion consisting of cyclosporine (a medication used to reduce transplant rejections or to treat arthritis and psoriasis) may be a cost-effective treatment for dry eye syndrome that does not respond to other therapies, according to a report in the February issue of Archives of Ophthalmology.

9 Feb 2009

Laser eye surgery comes under close scrutiny

More and more people are having laser vision corrective surgery (LASIK surgery) in the hope that their vision will be restored to such an extent that glasses will no longer be needed.

28 Apr 2008

Chronic dry eye syndrome after LASIK

Scientists at Schepens Eye Research Institute have found that people with a certain low level of tear production are more likely to develop chronic dry eye syndrome after LASIK (laser-assisted in situ keratomileusis), laser refractive surgery to correct near- and far-sightedness than those with more plentiful tears.

4 Mar 2008

Role gound for glaucoma gene and a signaling pathway

Researchers have found that a gene and a related signaling pathway play a role in the development of glaucoma, which is a common cause of visual impairment and blindness worldwide.

18 Feb 2008

Alpha-linolenic acid good for dry eye syndrome

Research conducted by Massachusetts Eye and Ear Infirmary (MEEI) Cornea Service Director and Harvard Medical School Professor Reza Dana, M.D., M. Sc., MPH, and colleagues at the Schepens Eye Research Institute have found for the first time that topical drop application of alpha-linolenic acid (ALA) led to a significant decrease in clinical signs of dry eye syndrome (DES) in animal models.

12 Feb 2008

Common medications could cause dry eye experts say

Common oral and topical medications could be causing dry eye in patients, according to optometrists.

22 Nov 2007

Sirion Therapeutics starts phase III clinical trials of pipeline compounds

Sirion Therapeutics has announced that it has initiated new phase III clinical programs for two of its pipeline compounds, ST-601 (difluprednate) and ST-603 (cyclosporine).

2 May 2007

Novagali Pharma announces FDA clearance of trial for treatment of dry eye syndrome

Novagali Pharma has announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase III clinical trial of its Cyclosporine A ocular product, Nova22007, has been granted by the U.S. Food and Drug Administration (FDA).

27 Apr 2007

Dry eye remedy

If you don't suffer from dry eye syndrome (DES), chances are you've never heard of it.

20 Apr 2007

Lexicon Reports on anti-angiogenesis target discoveries

Lexicon Genetics has presented results from the company's genetic screen to identify proteins involved in blood vessel formation and organization.

18 Apr 2007

Study sheds light on complex design of tears

It's no secret why we shed tears. But exactly what our tears are made of has remained a mystery to scientists.

28 Jan 2007

Plasminogen activator inhibitor type 2 may play role in infection and dry eye

Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye.

17 May 2006